Efficacy of first-line targeted therapy in real-world Korean patients with metastatic renal cell carcinoma

Focus on sunitinib and pazopanib

Myung Soo Kim, Ho Seok Chung, Eu Chang Hwang, Seung Il Jung, Dong Deuk Kwon, Jun Eul Hwang, Woo Kyun Bae, Jae Young Park, Chang Wook Jeong, Cheol Kwak, Cheryn Song, Seong Il Seo, Seok Soo Byun, Sung Hoo Hong, Jinsoo Chung

Research output: Contribution to journalArticle

Abstract

Background: To evaluate survival outcomes and prognostic factors for overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC) who received sunitinib (SU) and pazopanib (PZ) as first-line therapy in real-world Korean clinical practice. Methods: Data of 554 patients with mRCC who received SU or PZ at eight institutions between 2012 and 2016 were retrospectively reviewed. Based on the targeted therapy, the patients were divided into SU (n = 293) or PZ (n = 261) groups, and the clinicopathological variables and survival rates of the two groups were compared. A multivariable Cox proportional hazard model was used to determine the prognostic factors for OS. Results: The median follow-up was 16.4 months (interquartile range, 8.3-31.3). Patients in the PZ group were older, and no significant difference was observed in the performance status (PS) between the two groups. In the SU group, the dose reduction rate was higher and the incidence of grade 3 toxicity was more frequent. The objective response rates were comparable between the two groups (SU, 32.1% vs. PZ, 36.4%). OS did not differ significantly between the two groups (SU, 36.5 months vs. PZ, 40.2 months; log-rank, P = 0.955). Body mass index, Eastern Cooperative Oncology Group PS > 2, synchronous metastasis, poor Heng risk criteria, and liver and bone metastases were associated with a shorter OS. Conclusion: Our real-world data of Korean patients with mRCC suggested that SU and PZ had similar efficacies as first-line therapy for mRCC. However, PZ was better tolerated than SU in Korean patients.

Original languageEnglish
Article numbere325
JournalJournal of Korean Medical Science
Volume33
Issue number51
DOIs
Publication statusPublished - 2018 Jan 1

Fingerprint

Renal Cell Carcinoma
Survival
Therapeutics
Neoplasm Metastasis
sunitinib
pazopanib
Proportional Hazards Models
Body Mass Index
Survival Rate
Bone and Bones
Liver
Incidence

Keywords

  • Neoplasm metastasis
  • Pazopanib
  • Renal cell carcinoma
  • Sunitinib

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Efficacy of first-line targeted therapy in real-world Korean patients with metastatic renal cell carcinoma : Focus on sunitinib and pazopanib. / Kim, Myung Soo; Chung, Ho Seok; Hwang, Eu Chang; Jung, Seung Il; Kwon, Dong Deuk; Hwang, Jun Eul; Bae, Woo Kyun; Park, Jae Young; Jeong, Chang Wook; Kwak, Cheol; Song, Cheryn; Seo, Seong Il; Byun, Seok Soo; Hong, Sung Hoo; Chung, Jinsoo.

In: Journal of Korean Medical Science, Vol. 33, No. 51, e325, 01.01.2018.

Research output: Contribution to journalArticle

Kim, MS, Chung, HS, Hwang, EC, Jung, SI, Kwon, DD, Hwang, JE, Bae, WK, Park, JY, Jeong, CW, Kwak, C, Song, C, Seo, SI, Byun, SS, Hong, SH & Chung, J 2018, 'Efficacy of first-line targeted therapy in real-world Korean patients with metastatic renal cell carcinoma: Focus on sunitinib and pazopanib', Journal of Korean Medical Science, vol. 33, no. 51, e325. https://doi.org/10.3346/jkms.2018.33.e325
Kim, Myung Soo ; Chung, Ho Seok ; Hwang, Eu Chang ; Jung, Seung Il ; Kwon, Dong Deuk ; Hwang, Jun Eul ; Bae, Woo Kyun ; Park, Jae Young ; Jeong, Chang Wook ; Kwak, Cheol ; Song, Cheryn ; Seo, Seong Il ; Byun, Seok Soo ; Hong, Sung Hoo ; Chung, Jinsoo. / Efficacy of first-line targeted therapy in real-world Korean patients with metastatic renal cell carcinoma : Focus on sunitinib and pazopanib. In: Journal of Korean Medical Science. 2018 ; Vol. 33, No. 51.
@article{7ad8c18fc39e49eea076c4ade6571235,
title = "Efficacy of first-line targeted therapy in real-world Korean patients with metastatic renal cell carcinoma: Focus on sunitinib and pazopanib",
abstract = "Background: To evaluate survival outcomes and prognostic factors for overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC) who received sunitinib (SU) and pazopanib (PZ) as first-line therapy in real-world Korean clinical practice. Methods: Data of 554 patients with mRCC who received SU or PZ at eight institutions between 2012 and 2016 were retrospectively reviewed. Based on the targeted therapy, the patients were divided into SU (n = 293) or PZ (n = 261) groups, and the clinicopathological variables and survival rates of the two groups were compared. A multivariable Cox proportional hazard model was used to determine the prognostic factors for OS. Results: The median follow-up was 16.4 months (interquartile range, 8.3-31.3). Patients in the PZ group were older, and no significant difference was observed in the performance status (PS) between the two groups. In the SU group, the dose reduction rate was higher and the incidence of grade 3 toxicity was more frequent. The objective response rates were comparable between the two groups (SU, 32.1{\%} vs. PZ, 36.4{\%}). OS did not differ significantly between the two groups (SU, 36.5 months vs. PZ, 40.2 months; log-rank, P = 0.955). Body mass index, Eastern Cooperative Oncology Group PS > 2, synchronous metastasis, poor Heng risk criteria, and liver and bone metastases were associated with a shorter OS. Conclusion: Our real-world data of Korean patients with mRCC suggested that SU and PZ had similar efficacies as first-line therapy for mRCC. However, PZ was better tolerated than SU in Korean patients.",
keywords = "Neoplasm metastasis, Pazopanib, Renal cell carcinoma, Sunitinib",
author = "Kim, {Myung Soo} and Chung, {Ho Seok} and Hwang, {Eu Chang} and Jung, {Seung Il} and Kwon, {Dong Deuk} and Hwang, {Jun Eul} and Bae, {Woo Kyun} and Park, {Jae Young} and Jeong, {Chang Wook} and Cheol Kwak and Cheryn Song and Seo, {Seong Il} and Byun, {Seok Soo} and Hong, {Sung Hoo} and Jinsoo Chung",
year = "2018",
month = "1",
day = "1",
doi = "10.3346/jkms.2018.33.e325",
language = "English",
volume = "33",
journal = "Journal of Korean Medical Science",
issn = "1011-8934",
publisher = "Korean Academy of Medical Science",
number = "51",

}

TY - JOUR

T1 - Efficacy of first-line targeted therapy in real-world Korean patients with metastatic renal cell carcinoma

T2 - Focus on sunitinib and pazopanib

AU - Kim, Myung Soo

AU - Chung, Ho Seok

AU - Hwang, Eu Chang

AU - Jung, Seung Il

AU - Kwon, Dong Deuk

AU - Hwang, Jun Eul

AU - Bae, Woo Kyun

AU - Park, Jae Young

AU - Jeong, Chang Wook

AU - Kwak, Cheol

AU - Song, Cheryn

AU - Seo, Seong Il

AU - Byun, Seok Soo

AU - Hong, Sung Hoo

AU - Chung, Jinsoo

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background: To evaluate survival outcomes and prognostic factors for overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC) who received sunitinib (SU) and pazopanib (PZ) as first-line therapy in real-world Korean clinical practice. Methods: Data of 554 patients with mRCC who received SU or PZ at eight institutions between 2012 and 2016 were retrospectively reviewed. Based on the targeted therapy, the patients were divided into SU (n = 293) or PZ (n = 261) groups, and the clinicopathological variables and survival rates of the two groups were compared. A multivariable Cox proportional hazard model was used to determine the prognostic factors for OS. Results: The median follow-up was 16.4 months (interquartile range, 8.3-31.3). Patients in the PZ group were older, and no significant difference was observed in the performance status (PS) between the two groups. In the SU group, the dose reduction rate was higher and the incidence of grade 3 toxicity was more frequent. The objective response rates were comparable between the two groups (SU, 32.1% vs. PZ, 36.4%). OS did not differ significantly between the two groups (SU, 36.5 months vs. PZ, 40.2 months; log-rank, P = 0.955). Body mass index, Eastern Cooperative Oncology Group PS > 2, synchronous metastasis, poor Heng risk criteria, and liver and bone metastases were associated with a shorter OS. Conclusion: Our real-world data of Korean patients with mRCC suggested that SU and PZ had similar efficacies as first-line therapy for mRCC. However, PZ was better tolerated than SU in Korean patients.

AB - Background: To evaluate survival outcomes and prognostic factors for overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC) who received sunitinib (SU) and pazopanib (PZ) as first-line therapy in real-world Korean clinical practice. Methods: Data of 554 patients with mRCC who received SU or PZ at eight institutions between 2012 and 2016 were retrospectively reviewed. Based on the targeted therapy, the patients were divided into SU (n = 293) or PZ (n = 261) groups, and the clinicopathological variables and survival rates of the two groups were compared. A multivariable Cox proportional hazard model was used to determine the prognostic factors for OS. Results: The median follow-up was 16.4 months (interquartile range, 8.3-31.3). Patients in the PZ group were older, and no significant difference was observed in the performance status (PS) between the two groups. In the SU group, the dose reduction rate was higher and the incidence of grade 3 toxicity was more frequent. The objective response rates were comparable between the two groups (SU, 32.1% vs. PZ, 36.4%). OS did not differ significantly between the two groups (SU, 36.5 months vs. PZ, 40.2 months; log-rank, P = 0.955). Body mass index, Eastern Cooperative Oncology Group PS > 2, synchronous metastasis, poor Heng risk criteria, and liver and bone metastases were associated with a shorter OS. Conclusion: Our real-world data of Korean patients with mRCC suggested that SU and PZ had similar efficacies as first-line therapy for mRCC. However, PZ was better tolerated than SU in Korean patients.

KW - Neoplasm metastasis

KW - Pazopanib

KW - Renal cell carcinoma

KW - Sunitinib

UR - http://www.scopus.com/inward/record.url?scp=85058602379&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058602379&partnerID=8YFLogxK

U2 - 10.3346/jkms.2018.33.e325

DO - 10.3346/jkms.2018.33.e325

M3 - Article

VL - 33

JO - Journal of Korean Medical Science

JF - Journal of Korean Medical Science

SN - 1011-8934

IS - 51

M1 - e325

ER -